ArticleCureus2024
The Role of Maternal Serum Ferritin in Gestational Diabetes Mellitus in Southeast Asia.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Gestational diabetes mellitus (GDM) poses a significant health concern due to the numerous risks it presents to both the mother and fetus. While serum ferritin typically declines in cases of iron deficiency anemia, which is common during pregnancy, it may increase in the presence of inflammation. This study aims to evaluate the significance of serum ferritin in the context of GDM, considering its multifaceted role in these interconnected conditions. Methodology This cross-sectional study included pregnant women attending an obstetrics clinic for an oral glucose tolerance test at Hospital Canselor Tuanku Muhriz in Kuala Lumpur, Malaysia. With consent, demographic data, risk factors for GDM, and blood samples were collected. Blood samples were analyzed for serum ferritin, fasting blood glucose, two-hour post-glucose levels, and full blood count. The assessment of risk factors for GDM and the diagnosis of GDM adhered to Malaysian guidelines. The Mann-Whitney U test was employed to compare variables between the GDM and non-gestational diabetes mellitus (non-GDM) groups. Additionally, univariate and multivariate regression analyses were conducted to investigate the role of serum ferritin in GDM. All analyses were performed using IBM SPSS Statistics for Windows, Version 28.0 (Released 2021; IBM Corp., Armonk, NY, USA), with statistical significance set at p < 0.05. Results Among 172 pregnant women with an average gestational age of 23.6 weeks, the incidence of GDM was higher in those with risk factors (84.8%) compared to non-GDM participants (75.5%). Women with GDM had a slightly higher mean serum ferritin level (50.24 ± 29.00 ng/mL) than those without GDM (45.00 ± 58.69 ng/mL). However, ferritin levels did not significantly differ between the GDM and non-GDM groups (p = 0.669) or between those with and without risk factors (p = 0.374). While a higher BMI (OR: 0.832, p = 0.017) and ferritin (OR: 1.022, p = 0.031) levels independently predicted GDM, the predictive value of ferritin was borderline significant when combined with glucose tests (area under the curve = 0.689, p = 0.051). Conclusions Higher maternal serum ferritin levels in the mid-trimester are associated with increased BMI and GDM. However, maternal serum ferritin is most effective at predicting the incidence of GDM when used alongside standard glucose measurements, especially in women with elevated BMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.